August 18, 2020

Well done to the ATXA Team, who gave a presentation at the World Orphan Drug Virtual Conference on Monday 17th August. They presented on NTP42 an antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension (PAH).

August 5, 2020

ATXA Therapeutics & PAH Hope are delighted to welcome Jonathan Langley on board as a non-executive director. Jonathan has vast experience in Pulmonary Arterial Hypertension.

Please reload

Recent Posts

September 30, 2019

Please reload

Please reload

Search By Tags
Please reload

© 2020 by ATXA Therapeutics Limited.

Dublin, Ireland

Home  |  About Us  |  News  |  Contact Us

Follow us on:

  • LinkedIn Social Icon
  • Facebook Social Icon
  • Twitter Social Icon